PL321737A1 - Application of carbazoles for treating haemostatic cardiac insufficiency - Google Patents

Application of carbazoles for treating haemostatic cardiac insufficiency

Info

Publication number
PL321737A1
PL321737A1 PL96321737A PL32173796A PL321737A1 PL 321737 A1 PL321737 A1 PL 321737A1 PL 96321737 A PL96321737 A PL 96321737A PL 32173796 A PL32173796 A PL 32173796A PL 321737 A1 PL321737 A1 PL 321737A1
Authority
PL
Poland
Prior art keywords
carbazoles
haemostatic
treating
application
cardiac insufficiency
Prior art date
Application number
PL96321737A
Other languages
English (en)
Inventor
Mary Ann Lukas-Laskey
Robert Ruffolo Jr
Neil Shusterman
Gisbert Sponer
Klaus Strein
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL321737(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of PL321737A1 publication Critical patent/PL321737A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL96321737A 1995-02-08 1996-02-07 Application of carbazoles for treating haemostatic cardiac insufficiency PL321737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure
PCT/EP1996/000498 WO1996024348A2 (en) 1995-02-08 1996-02-07 Use of carbazole compounds for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
PL321737A1 true PL321737A1 (en) 1997-12-22

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96321737A PL321737A1 (en) 1995-02-08 1996-02-07 Application of carbazoles for treating haemostatic cardiac insufficiency

Country Status (26)

Country Link
US (6) US5760069A (xx)
EP (1) EP0808162B1 (xx)
JP (1) JP3546058B2 (xx)
KR (1) KR100295940B1 (xx)
CN (1) CN1093760C (xx)
AT (1) ATE179891T1 (xx)
AU (1) AU702106C (xx)
BR (1) BR9607111A (xx)
CA (1) CA2212548C (xx)
CZ (1) CZ292002B6 (xx)
DE (1) DE69602424T2 (xx)
DK (1) DK0808162T3 (xx)
ES (1) ES2134588T3 (xx)
FI (1) FI973255A0 (xx)
GR (1) GR3030966T3 (xx)
HU (1) HUP9900773A3 (xx)
NO (1) NO314830B1 (xx)
NZ (1) NZ301692A (xx)
PL (1) PL321737A1 (xx)
RO (1) RO121629B1 (xx)
RU (1) RU2197242C2 (xx)
SI (1) SI0808162T1 (xx)
SK (1) SK106897A3 (xx)
UA (1) UA55382C2 (xx)
WO (1) WO1996024348A2 (xx)
ZA (1) ZA96994B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
NZ335080A (en) * 1996-10-09 2000-04-28 Boehringer Mannheim Pharm Corp Use of dual non-selective beta-adrenoceptor and alpha1-adrenoceptor for inhibiting stress activated protein kinases(SAPK)
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
CN1285738A (zh) * 1997-11-12 2001-02-28 泊灵格曼海姆药品公司及史密斯克莱恩贝克曼公司 卡维地洛的新的口服剂型
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US6465463B1 (en) * 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
CA2386954C (en) * 1999-10-29 2011-12-13 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
AU2001271639A1 (en) 2000-06-28 2002-01-08 Teva Pharmaceutical Industries Ltd. Carvedilol
US20050009897A1 (en) * 2001-04-02 2005-01-13 Karen Anderson Method of treatment
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
EP1465620A4 (en) * 2001-10-02 2006-01-25 Smithkline Beecham Corp NEW COMPOSITION OF CARVEDILOL
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
CA2472377A1 (en) * 2002-01-15 2003-07-24 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
RU2203063C1 (ru) * 2002-03-12 2003-04-27 Нестерук Владимир Викторович Способ получения твердой лекарственной формы препарата, обладающего диуретическим действием
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US6951880B2 (en) * 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
CN103254114A (zh) * 2002-06-27 2013-08-21 史密斯克莱.比奇曼（科克）有限公司 卡维地洛磷酸盐和/或其溶剂合物相应的组合物和/或治疗方法
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
ATE257384T1 (de) * 2002-07-25 2004-01-15 Boehringer Ingelheim Pharma Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
CA2573562A1 (en) * 2004-07-16 2006-02-23 Nitromed, Inc. Compositions and methods related to heart failure
KR20070088507A (ko) * 2005-06-09 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 카베딜올의 결정질 형태 및 이것의 제조 방법
CA2634473A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) * 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
US20090306081A1 (en) * 2006-05-16 2009-12-10 Letts L Gordon Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
EP2114881A1 (en) * 2007-02-26 2009-11-11 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
CA2992219A1 (en) 2010-04-12 2011-10-20 Supernus Pharmaceuticals Inc. Methods for producing viloxazine salts and novel polymorphs thereof
AU2012296925A1 (en) 2011-08-12 2014-02-06 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
CN110381929A (zh) * 2016-06-13 2019-10-25 阿森迪亚制药有限责任公司 卡维地洛分散系统的肠胃外缓释传递
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
RU2058144C1 (ru) * 1988-12-15 1996-04-20 Центр по химии лекарственных средств Средство для лечения сердечной недостаточности
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
RU2032685C1 (ru) * 1991-12-16 1995-04-10 Центр по химии лекарственных средств Производные пиридо (3,2-а)карбазола, обладающие кардиотонической активностью
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
NO973667D0 (no) 1997-08-08
US5760069A (en) 1998-06-02
AU702106C (en) 2005-02-17
SI0808162T1 (en) 1999-10-31
USRE40707E1 (en) 2009-05-05
RO121629B1 (ro) 2008-01-30
HUP9900773A3 (en) 2000-04-28
US20030105138A1 (en) 2003-06-05
JP3546058B2 (ja) 2004-07-21
US20010044455A1 (en) 2001-11-22
RU2197242C2 (ru) 2003-01-27
DE69602424D1 (de) 1999-06-17
DK0808162T3 (da) 1999-11-15
JPH10513463A (ja) 1998-12-22
CA2212548C (en) 1999-08-24
ES2134588T3 (es) 1999-10-01
NZ301692A (en) 2000-09-29
DE69602424T2 (de) 1999-10-07
GR3030966T3 (en) 1999-11-30
NO973667L (no) 1997-08-08
UA55382C2 (uk) 2003-04-15
HK1014861A1 (en) 1999-10-08
CZ246397A3 (cs) 1998-11-11
CN1185106A (zh) 1998-06-17
WO1996024348A3 (en) 1996-10-03
CZ292002B6 (cs) 2003-07-16
ATE179891T1 (de) 1999-05-15
SK106897A3 (en) 1999-03-12
MX9706042A (es) 1998-06-30
FI973255A7 (fi) 1997-08-07
US5902821A (en) 1999-05-11
KR100295940B1 (ko) 2001-08-07
EP0808162A2 (en) 1997-11-26
AU702106B2 (en) 1999-02-11
HUP9900773A2 (hu) 1999-07-28
WO1996024348A2 (en) 1996-08-15
EP0808162B1 (en) 1999-05-12
FI973255A0 (fi) 1997-08-07
AU4718196A (en) 1996-08-27
CA2212548A1 (en) 1996-08-15
KR19980702085A (ko) 1998-07-15
ZA96994B (en) 1997-10-27
BR9607111A (pt) 1997-11-04
NO314830B1 (no) 2003-06-02
CN1093760C (zh) 2002-11-06
USRE40000E1 (en) 2008-01-08

Similar Documents

Publication Publication Date Title
PL321737A1 (en) Application of carbazoles for treating haemostatic cardiac insufficiency
NO20010844L (no) Regulering av substrataktivitet
WO1997036609A3 (en) Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
ZA925698B (en) Treatment of congestive heart failure.
AU2003202857A1 (en) Method and apparatus for measuring left ventricular pressure
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
IE901594L (en) Azaindenes
NO961478D0 (no) Levobupivacaine anvendelig for kontroll av kronisk smerte
IE790951L (en) Carnitine solution
EP0746313A4 (en) METHOD FOR TREATING SMALL Mouth Ulcers
Kellner et al. Weekly ECT in geriatric depression
TW221445B (xx)
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
EE9700231A (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
FR2794656B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur ou cardioverteur de type multisite , comportant des moyens de stimulation resynchronisee pour le traitement de l'insuffisance cardiaque
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
NO20024545D0 (no) Fremgangsmåte for behandling av kongestiv hjertefeil
UA35912A (uk) Спосіб лікування виразкової хвороби шлунку та дванадцятипалої кишки
ES8500055A1 (es) Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.
UA30329A (uk) Спосіб лікування хронічних запальних захворювань придатків матки
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
王以仁 et al. Short-Term Effect of Lansoprazole on Intragastric Acidity in Duodenal Ulcer Patients
UA28928A (uk) Спосіб лікування гнійно-запальних захворювань м'яких тканин
UA16000A1 (uk) Спосіб лікуваhhя гіпотрофії поросят